Aetna International is set to take over Aviva UK’s IPMI division

By Catherine Sturman
Leading global health care benefits provider, Aetna International has entered an agreement to acquire Aviva UK’s International Private Medical Insuran...

Leading global health care benefits provider, Aetna International has entered an agreement to acquire Aviva UK’s International Private Medical Insurance (IPMI) operations. From May 2018, Aviva UK will no longer provide IPMI cover for new customers or for existing customers wishing to renew their policies. 

Serving over 700,000 million members worldwide, Aetna International offers a multitude of services, delivering comprehensive health care benefits, alongside customised technological and health management solutions, covering health care systems, government entities and large employers.

Under the agreement, existing Aviva IPMI customers will be offered continuation terms at policy renewal with Aetna International. Existing Aviva customers who renew their policy will then become Aetna customers and will no longer have a relationship with Aviva.

See also

David Healy, CEO EMEA at Aetna International said: “We are delighted to have reached this agreement with Aviva. 

We are committed to delivering Aviva’s IPMI customers continuation of cover with Aetna that provides comparable benefits and an excellent level of service. This is very much in line with our business strategy to deliver comprehensive health care benefits worldwide.

Our scale, expertise, customer service infrastructure and technological focus in IPMI allow us to make a significant contribution to improving people’s health and the quality of care they receive.”

Share

Featured Articles

McKinsey Health Institute: Focus on Healthcare Insights Body

McKinsey Health Institute generates healthcare insights that McKinsey's consulting teams can draw upon for the benefit of its customers

AstraZeneca & Celonis Map out Digital Transformation

AstraZeneca's Raaj Joshi discusses sustainable innovation in pharmaceutical manufacturing & the company's digital transformation, undertaken with Celonis

Google DeepMind's AlphaFold 3 'is Drug Discovery Boost'

Google DeepMind's AlphaFold 3 is an AI model that can predict the structures and interactions of molecules and will help scientists unlock new medicines

UnitedHealth CEO Admits Hack hit Third of US Citizens' Data

Digital Healthcare

Why Sanofi Leads the way on Healthcare Sustainability

Sustainability

Philips Q1 Results hit by $1.1bn Respironics Settlement

Medical Devices & Pharma